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Abstract
Effective anti-malarial drug treatment reduces malaria transmission. This alone can reduce the
incidence and prevalence of malaria, although the effects are greater in areas of low transmission
where a greater proportion of the infectious reservoir is symptomatic and receives anti-malarial
treatment. Effective treatment has greater effects on the transmission of falciparum malaria, where
gametocytogenesis is delayed, compared with the other human malarias in which peak
gametocytaemia and transmissibility coincides with peak asexual parasite densities. Mature
Plasmodium falciparum gametocytes are more drug resistant and affected only by artemisinins and
8-aminoquinolines. The key operational question now is whether primaquine should be added to
artemisinin combination treatments for the treatment of falciparum malaria to reduce further the
transmissibility of the treated infection. Radical treatment with primaquine plays a key role in the
eradication of vivax and ovale malaria. More evidence is needed on the safety of primaquine when
administered without screening for G6PD deficiency to inform individual and mass treatment
approaches in the context of malaria elimination programmes.
Background
Anti-malarial drugs play a central role in the control and
ultimate elimination of malaria, but, in most circum-
stances, they cannot do the job alone. Whether malaria
can be eliminated with current tools is a subject of active
debate [1], but it is generally agreed that the tools to
reduce substantially the global burden of malaria are
available. The corollary is that if the current classes of
effective anti-malarial drugs (notably the artemisinin
derivatives) are lost, then effective control and elimina-
tion will not be possible. Anti-malarials, if effective,
reduce the transmission of malaria, but the relationship
between efficacy and transmission reduction is not
straightforward. This relationship is the subject of this
review.
Epidemiological considerations
Where transmission of malaria is intense, even highly
effective interventions which reduce mortality may have
little noticeable effect on the clinical pattern of malaria. A
95% reduction in transmission from 500 infective bites
per year to 25 will not change the incidence or prevalence
of malaria noticeably. In this context, there is a tremen-
dous redundancy in the transmission reservoir (from
asymptomatic gametocyte carriers), and the use of effec-
tive anti-malarial drugs will have relatively little impact
on transmission intensity. For example, in a high trans-
mission setting in Western Kenya, it was estimated, based
on mosquito feeding studies, that 28% of all transmission
derived from children ≥10 years and adults – a largely
asymptomatic population [2]. This would correspond to
10–50 infectious bites per year, plenty to sustain a hyper
or holoendemic pattern of malaria even if every sympto-
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matic patient received highly effective drugs. But as trans-
mission intensity falls, the premunition of the population
declines, and an increasing proportion of transmission
derives from symptomatic individuals, who will seek anti-
malarial treatment. In a detailed epidemiological study
conducted in a low transmission setting on the Thai-Bur-
mese border (entomological inoculation rate <1 per spe-
cies) all P. falciparum infections were symptomatic, but
approximately 10% of Plasmodium vivax infections were
still asymptomatic [3]. Although this is probably repre-
sentative of most low transmission settings, it is impor-
tant to note that transmission intensity is remarkably
heterogeneous over short geographic distances, and that
low transmission areas usually contain small foci of much
higher transmission intensity which act as reservoirs of
infection. Inhabitants of these small foci sustain malaria
over the annual dry season. Premunition does not change
abruptly, so if there are sudden decreases (or increases) in
transmission intensity then the changes in clinical epide-
miology lag behind (hysteresis). Thus, the effects of anti-
malarial treatment on the incidence and prevalence of
malaria increase as transmission falls. Unfortunately,
there are no precise estimates of this relationship.
Biological considerations
As human malaria is transmitted by sexual stages of the
parasites, not asexual stages, infecting anopheline mos-
quito vectors, transmission depends upon the duration
for which gametocytes are carried in the blood, the infec-
tivity of this gametocytaemia to the local vectors, and the
abundance and behaviour of the vectors [4]. The attrac-
tiveness of humans to mosquitoes is unevenly distributed
amongst the human population. Mosquitoes apparently
prefer to bite individuals with lower biomass and lower
body surface area [5], pregnant women [6], and those
with smelly feet [7,8], amongst other things. Gametocy-
taemia is detectable by microscopy down to densities of
approximately 10–20/uL. At least one male gametocyte's
progeny (eight microgametes) and one female macrogam-
ete are required in a mosquito blood meal (approx 2–3
μL) for infection to occur. Thus, gametocyte densities of 1/
μL can theoretically infect vector mosquitoes [4,9]. This is
below the density which can be detected by routine micro-
scopy. It has sometimes been stated that malaria can be
transmitted (to mosquitoes) by individuals who are not
carrying gametocytes. This is impossible. What is actually
meant is that the individuals obviously were carrying via-
ble gametocytes in their blood, but the density was below
that detectable by microscopy [10]. As the progeny of at
least two gametes are required to form a zygote, the prob-
abilities of transmission as gametocyte densities fall
below 1/μL rapidly become vanishingly small. Whether
gametocytes concentrate in the dermal capillaries (as they
ought to!) still remains unclear, but even if they do, these
numerical considerations still apply. Plasmodium falci-
parum differs from the other three human malarias in two
important respects; first, gametocyte formation is delayed
with respect to the peak production of asexual stages [11-
13], and, second, that mature gametocytes are resistant to
most of the anti-malarial drugs, which affect asexual
stages. The developing sexual stages of P. falciparum
(stages I to IV) remain sequestered in the microvascula-
ture for approximately 10 days before appearing as mor-
phologically distinct male and female gametocytes (stage
5) in the peripheral blood. Peak transmissibility coincides
approximately with peak gametocytaemia [12]. Several
factors increase the production of gametocytes in falci-
parum malaria, most of which can be considered under
the general rubric of "stress"; these include long duration
of infection, anaemia, partially effective immune
responses, and partially effective drugs [14-17].
In infections with P. vivax, P. malariae and P. ovale, the
asexual and sexual stages appear almost together [18-20],
and, in contrast to P. falciparum [19], are sensitive to all
the drugs which kill the asexual stages [21] These three
malaria parasites transmit very efficiently at low parasite
densities – much more efficiently than P. falciparum. Thus,
a greater proportion of infected subjects without detecta-
ble gametocytaemia can transmit these malaria infections.
Because the majority of patients presenting with these so-
called benign malarias are already infective to biting
anopheline mosquito vectors when they present ill for
treatment, administration of effective anti-malarial drugs
has less effect on overall transmission compared with fal-
ciparum malaria.
Pharmacological considerations
All anti-malarial drugs which kill asexual stages also kill
the early stages of P. falciparum gametocytes, as well as the
mature P. vivax, malariae, and ovale gametocytes. Thus the
combination of reducing the asexual stage progenitors of
the sexual stages, and killing the gametocytes themselves
reduces transmissibility. In general, the asexual and sexual
stage activities parallel each other [21-24], although the
quantitative relationships between anti-malarial drug
concentrations (pharmacokinetics; PK) and reduction in
transmissibility (pharmacodynamics; PD) are not well
characterized [25], particularly for vivax, malariae, and
ovale infections. For fully sensitive asexual stage parasites,
the artemisinin derivatives produce the most rapid reduc-
tions in parasitaemia [26,27], followed by chloroquine
[28], then closely behind the other quinolines and related
drugs, together with atovaquone, and finally the antifols.
It is not clear whether amodiaquine, piperaquine and pyr-
onaridine are closer to chloroquine than quinine and
mefloquine in this batting order but if they are, the differ-
ences are small. The antibiotics with anti-malarial activity
are generally less active and clear parasitaemia more
slowly than the anti-malarial drugs [23]. At a populationMalaria Journal 2008, 7(Suppl 1):S8 http://www.malariajournal.com/content/7/S1/S8
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level there is wide inter-individual variation in the effects
of a single anti-malarial treatment on the reduction in par-
asitaemia. This derives from host differences in anti-
malarial adherence, absorption, distribution (drug elimi-
nation is less relevant), and splenic function as well as dif-
ferences in the numbers, stage, synchronicity and
susceptibility of the infecting parasites [26]. Anti-malarial
drug susceptibility of the infecting parasites becomes
important when the drug concentrations in blood do not
produce the maximum effect (i.e. are below the minimum
parasiticidal concentration; MPC). The proportion of
treated patients with blood concentrations below the
MPC is a function of drug quality, dose taken, host phar-
macokinetics, and resistance. As resistance worsens this
proportion increases [29].
The overall effects of anti-malarial drugs on P. falciparum
gametocytaemia (i.e. late stage gametocytes which circu-
late and are detectable by microscopy) is a composite of
their effects on the progenitors, the early (more drug sus-
ceptible) stage 1 to 3 sequestered gametocytes, and the
more mature (less drug susceptible) stages. P. falciparum
gametocytaemia following antifol treatment (best docu-
mented for sulphadoxine-pyrimethamine) is consistently
greater than that following other drug classes [4,30,31],
whereas treatment with the artemisinin derivatives is asso-
ciated with lower rates of gametocyte carriage
[13,14,27,32,33]. The 8-aminoquinolines (primaquine,
quinocide, tafenoquine) occupy a unique position. Most
data refer to primaquine, the only generally available
compound. Primaquine has reasonable asexual stage
activity against P. vivax malaria [34], kill hypnozoites of P.
vivax and P.ovale [35,36], and mature gametocytes of P.
falciparum [37,38], but importantly lacks useful activity
against asexual stages (and presumably early gameto-
cytes) of P. falciparum [37,38]. It is not known how pri-
maquine works in any of these three actions, nor which of
its many metabolites is the active moiety. The considera-
ble variations in immunity, pharmacokinetics and phar-
macodynamics results in marked variability in
transmissibility related to the activity of anti-malarial
drugs [39-43].
Anti-malarial drug resistance and transmissibility
In considering anti-malarial drug effects on transmissibil-
ity, three different components need to be considered; a)
activity against asexual stages and early gametocytes, b)
activity against mature infectious gametocytes, and c) spo-
rontocidal effects in the mosquito. As drug activity against
the asexual stage activity falls because of worsening anti-
malarial resistance, the rate at which parasitaemia is
reduced falls, and treatment failure rates increase. Game-
tocytaemia is a very sensitive measure of worsening drug
resistance. As SP resistance worsened in South Africa,
increasing gametocytaemia was the first warning sign.
Importantly it preceded measurable changes in parasite
clearance or a decline in cure rates [44]. Thus, transmis-
sion, and in particular transmission of resistance, would
have increased before detectable changes in treatment fail-
ure rates. Okell et al have recently pooled data from 3,174
patients enrolled in six anti-malarial trials conducted in
The Gambia and Kenya. ACT treatment (either artesunate-
SP, artesunate-chloroquine or artemether lumefantrine)
was associated with a significant reduction in the proba-
bility of being gametocytaemic on the day of transmission
experiments (OR 0.20 95% CI 0.16–0.26), transmission
to mosquitoes by slide-positive gametocyte carriers (OR
mosquito infection 0.49 95% CI 0.33–0.73), and AUC of
gametocyte density (ratio of means 0.35 95% CI 0.31–
0.41) [45]. Partially effective anti-malarial drug treatment
increases gametocyte carriage both by reducing asexual
parasite killing and by providing a stress on the surviving
asexual parasite population [16,17]. These factors allow a
greater fraction of asexual parasites to switch to gameto-
cyte development. The chance of an infection recrudesc-
ing also increases. Recrudescent infections are more likely
than primary infections to be gametocytaemic at presenta-
tion (because of the extended duration of infection, drug
"stress" and anaemia), and are also more likely to fail sub-
sequent treatment. The net result of the increased gameto-
cyte carriage of the primary infections, and any
subsequent recrudescences, is much greater gametocyte
carriage in infections caused by resistant parasites. This
translates (with considerable inter-individual variation)
into increased transmissibility. It is this transmission
advantage that drives the spread of resistance.
For antifols and atovaquone, there are also effects in the
mosquito to consider. These drugs prevent the formation
of sporozoites by interfering with oocyst development in
the anopheline mosquito[46,47]. Tafenoquine also has
sporontocidal activity and is more active than primaquine
which has little or no activity [48]. Antifol resistant para-
sites are more transmissible than antifol sensitive para-
sites in the presence of drug indicating a further location
of selective pressure driving the spread of antifol resist-
ance [49].
It is evident that anti-malarial drug resistance spreads
because of the greater transmission potential of the resist-
ant parasites in the presence of the anti-malarial drug.
Most currently available anti-malarial drugs are elimi-
nated slowly from the body and so, if they are used
intensely in a malaria endemic area, a significant propor-
tion of the community has variable concentrations of the
drug in their blood. These concentrations act as a selective
filter favouring the establishment of resistant infections.
The degree of selection depends on several factors includ-
ing the intensity of transmission, the immunity profile ofMalaria Journal 2008, 7(Suppl 1):S8 http://www.malariajournal.com/content/7/S1/S8
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the host and the pharmacokinetic and pharmacodynamic
properties of the anti-malarial drug.
Benefits of reducing transmission
Intense malaria is associated with a considerable burden
of morbidity and mortality in childhood. Infant mortality
rates are positively correlated with transmission intensity
measured by the EIR (estimated entomological inocula-
tion rate), although the exact relationship is not well
defined [50]. Mosquitoes may bite infants proportionally
more than adults; they have been shown to bite preferen-
tially individuals with lower biomass and lower body sur-
face [5,50]. Deployment of effective anti-malarial drugs
either alone or in combination with other control meas-
ures, particularly insecticide treated bed nets and indoor
residual spraying, reduces malaria morbidity and mortal-
ity [51-53]. Indeed, the introduction of effective malaria
control reduces the mortality rate more than would be
expected by the direct prevention of the malaria deaths
alone. This is explained by many of the conditions leading
to infant deaths being only indirectly or cumulatively
related to malaria, such as malaria anaemia and low birth
weight due to placental malaria. Importantly reducing
infant mortality does not seem to be balanced by higher
mortality later on [54]. Thus, there is overwhelming evi-
dence for a benefit from reducing malaria transmission.
Operational considerations
Artemisinin combination treatments are the recom-
mended first-line drugs for the treatment of falciparum
malaria in endemic areas. They are highly effective and
well tolerated, but despite considerable increases in recent
support for anti-malarial drugs, the majority of those that
need ACTs do not receive them. Scaling up deployment of
ACTs and insecticide-treated nets, and importantly subsi-
dizing ACTs so that the treatment is affordable, and
donating insecticide-treated nets, will have a major
impact on malaria morbidity and mortality. Indoor resid-
ual spraying also has a major role to play in some areas.
Should elimination programmes do anything different?
The outstanding unresolved question for treatment, is
whether a single "gametocytocidal" dose of primaquine
(0.5 to 0.75 mg base/kg) should be added to ACT for fal-
ciparum malaria treatment [55]. Addition of a single dose
of primaquine to first-line treatment has been recom-
mended by malaria control programmes in some areas,
but not others, for many years. Despite this there is
remarkably little evidence on either safety or efficacy. Pre-
vention of relapse in vivax and ovale infections, and thus
control of transmission, depends on taking a two-week
radical curative regimen of primaquine (i.e. 14 days of
0.25 to 0.5 mg base/kg/day). Again this is recommended
in some areas, and not in others.
Although uncertain efficacy, and the difficulty in ensuring
adherence to 14-day regimens, have lowered enthusiasm
for pursuing radical cure in endemic areas, the main reser-
vations which have limited the use of primaquine concern
safety. Primaquine predictably causes abdominal discom-
fort. The effect is dose-dependent, but considerably amel-
iorated by food. The 8-aminoquinolines are oxidant drugs
and cause oxidant haemolysis. Methaemoglobinaemia is
usual [56], but in inherited red cell enzyme deficiencies
which impair defences against oxidant stress, haemolysis
can be severe and occasionally life-threatening [57]. The
introduction of primaquine in 1951 led to the discovery
of glucose-6-phosphate dehydrogenase (G6PD) defi-
ciency, the most common human enzyme deficiency,
which affects approximately 400 million people world-
wide [58]. There are some 140 different genotypes of
G6PD deficiency [59,60] with corresponding phenoy-
types that vary from mild to severe. The extent of oxidant
haemolysis depends on the degree and nature of defi-
ciency. Enzyme deficiency protects against severe malaria
and so the abnormality is prevalent mainly in areas where
malaria is or was prevalent. It is often recommended that
G6PD deficiency testing be performed before administer-
ing treatment. In reality testing is usually unavailable. Sev-
eral rapid tests are available in theory (but deployment is
very limited) and there is insufficient evidence on their
sensitivity and specificity to recommend their general
deployment. The semi-quantitative fluorescence spot test
is more demanding but reliable, and quantitation requires
a spectrophotometric assay. So, in practice testing is usu-
ally unavailable and primaquine is often not given.
Mass treatment
Mass treatment of the entire population with anti-malar-
ial drugs was performed on many occasions in the eradi-
cation programmes of the 1950s and 1960s, and has been
employed sporadically since then. This experience has
been reviewed recently [61]. As a strategy it has not found
favour in recent years. The alternative proactive
approaches are mass screening and treatment (MST). This
has been preferred over mass treatment in Western Cam-
bodia in current efforts to contain and eliminate malaria
there. MST is a more logistically demanding approach,
and it assumes that most of the infectious reservoir will
have detectable parasitaemias at the time of screening.
Obviously, for P. vivax and P. ovale, screening will not
detect hypnozoite carriage. The advantages and disadvan-
tages of these two different approaches bear further exam-
ination and evaluation. Mass treatment and MST would
be more acceptable if toxicity concerns over administra-
tion of the 8 aminoquinolines, without screening for
G6PD deficiency, in the population can be overcome.Malaria Journal 2008, 7(Suppl 1):S8 http://www.malariajournal.com/content/7/S1/S8
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